#United States #New York #Class Action #The Gross Law Firm #Zenas BioPharma

Class Action Alert: Zenas BioPharma, Inc.

The Gross Law Firm has issued an important notice for shareholders of Zenas BioPharma, Inc.
(NASDAQ: ZBIO). If you acquired shares of ZBIO during the designated class period, now is the time to take action!

Key Details of the Class Action

The lawsuit pertains to individuals who purchased or obtained Zenas BioPharma securities in relation to the registration statement and accompanying prospectus issued during the company's initial public offering (IPO) in September 2024. The allegations within the complaint state that the company misrepresented significant financial details concerning its operational funding and cash reserves, leading to substantial misinformation in the public domain.

Specific Allegations

The complaint asserts that Zenas BioPharma:
1. Overseted Financial Viability: The firm inaccurately projected its capacity to finance operations using the available cash and expected proceeds from the IPO. This claim calls into question the integrity of the company’s financial statements and the ethical obligations of its leadership.
2. Misleading Public Statements: As a result of these inaccuracies, the statements made to the public by the defendants were misleading, creating an artificially inflated stock price.

Important Deadlines to Note

The deadline for shareholders to join this important class action is set for June 16, 2025. It is crucial that interested parties register without delay to avoid missing this opportunity for potential recovery. You can find the registration form here.

Next Steps for Shareholders

Once registered as a shareholder who purchased shares during the specified timeframe, participants will be enrolled in a monitoring service that provides regular updates regarding the status of the case. This initiative reflects the commitment of The Gross Law Firm to keep shareholders informed throughout the legal process.

Why Choose The Gross Law Firm?

The Gross Law Firm has built a reputation as a leading class action law firm focused on protecting investors' rights against corporate misconduct. With a strong track record of advocating for shareholder interests, the firm aims to ensure companies act responsibly and transparently. The firm strives for recovery on behalf of investors who suffered losses due to deceptive practices. It is essential to highlight that being appointed a lead plaintiff is not a requirement for participating in this lawsuit.

Contact Information

For more details or inquiries, interested parties should reach out to The Gross Law Firm at:

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903

Conclusion

The potential impact of this class action could be significant for shareholders of Zenas BioPharma, given the alleged discrepancies in financial reporting. Shareholders are strongly encouraged to take advantage of this opportunity to protect their investments and join the lawsuit before the approaching deadline.